This is to inform you that shareholders of the company have approved the appointment of Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals has informed the stock exchange that shareholders have approved the appointment of Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director of the company through a postal ballot, results declared on January 2, 2026. The appointment was originally made by the Board effective January 1, 2026, for a consecutive term of 5 years. Dr. Moolemath holds a PhD in Toxicology, is a European Registered Toxicologist with over 30 years of experience in drug discovery, development, and regulatory science, and currently serves as Chief Scientific Officer & Co-Founder of Vittarthaa Life Sciences. He is not related to any existing directors on the board.
This is a routine governance update confirming shareholder ratification of an independent director's appointment. It strengthens board composition with scientific expertise but is unlikely to have a material impact on the stock price.